TABLE 4.

Incidence of Grade 3–4 Laboratory Abnormalities During ¹⁷⁷Lu-PSMA Therapy

Abnormality	All patients	Time between end of ²²³Ra and start of ¹⁷⁷Lu-PSMA^*
Abnormality	All patients	<6 mo	≥6 mo
Anemia	40/133 (30%)	14/42 (33%)	25/90 (28%)
Thrombocytopenia	17/133 (13%)^†	5/42 (12%)	12/90 (13%)
Neutropenia	3/130 (2%)	2/41 (5%)	1/88 (1%)
ASAT elevation	2/131 (2%)	1/42 (2%)	1/88 (1%)

↵* Time between therapies was unknown in 1 patient and therefore not included in this analysis.
↵† Eight of 17 patients had thrombocytopenia at start of ¹⁷⁷Lu-PSMA.
ASAT = aspartate aminotransferase.
Data are from start of ¹⁷⁷Lu-PSMA treatment to 90 d after last dose.